Podcasts about Working group

Assuming we already understand the parameters of “good citizenship” (obey the law; do no harm to others), how to decide what constitutes a “well-informed” citizen? Tom Schnaubelt, executive director of Hoover's Revitalizing American Institutions (RAI) initiative, and Checker Finn, a Hoover senior fellow and chair of Hoover's Working Group on Civics and American Citizenship, introduce Hoover's pioneering “Civic Profile” which launches in early March – a three-part test that assesses civics-related values, knowledge, and engagement. Also discussed: how to keep the civics “push” going past the coming American semi-quincentennial in early July (is a decades-long “civics renaissance” feasible?), plus other RAI endeavors currently underway at Hoover (national civics fellows, a networking Alliance for Civics in the Academy, “People, Politics and Places” fellowships that bring rural undergrad and grad students to the Stanford University campus, plus Hoover's USA @ 250 lecture series on ideas, institutions, and civic traditions that have sustained America freedom dating back to the republic's founding).   Recorded on February 25, 2026.  ABOUT THE SPEAKERS Chester E. Finn Jr. is the Volker Senior Fellow (adjunct) at the Hoover Institution and President Emeritus of the Thomas B. Fordham Institute. At Hoover, he chairs the Working Group on Civics and American Citizenship within the Center for Revitalizing American Institutions. He previously led Hoover's Task Force on K-12 Education and now participates in the Hoover Education Success Initiative, as much of his career has focused on reforming primary and secondary schooling in the US. That included serving as a member of the Maryland State Board of Education and Maryland's Commission on Innovation and Excellence in Education, as well as Assistant US Secretary of Education and chair of the National Assessment Governing Board. Thomas Schnaubelt is the Executive Director of the Center for Revitalizing American Institutions at the Hoover Institution. Prior to his role at the Hoover Institution, Schnaubelt served as a Lecturer and Senior Advisor on Civic Education at the Deliberative Democracy Lab, within the Center for Democracy, Development, and the Rule of Law at the Freeman Spogli Institute for International Studies. Schnaubelt came to Stanford in 2009 and has served as the Associate Vice Provost for Education, the Executive Director of the Haas Center for Public Service, and a Resident Fellow in Branner Hall, where he and his wife oversaw the development and implementation of a living-learning community focused on public service and civic engagement. In 2015, Schnaubelt coordinated the launch of Cardinal Service, a university wide effort to elevate and expand public service as a distinctive feature of the Stanford experience, and he has launched and led several national initiatives focused on democratic engagement and social change education. Schnaubelt received a Ph.D. in Educational Leadership from the University of Mississippi, a Master of Arts in Education from the University of Michigan, and Bachelor of Science in Physics from the University of Wisconsin-Stevens Point. Bill Whalen, the Virginia Hobbs Carpenter Distinguished Policy Fellow in Journalism and a Hoover Institution research fellow since 1999, writes and comments on campaigns, elections, and governance with an emphasis on California and America's political landscapes. Whalen writes on politics and current events for various national publications, as well as Hoover's California On Your Mind web channel. Whalen hosts Hoover's Matters of Policy & Politics podcast and serves as the moderator of Hoover's GoodFellows broadcast exploring history, economics, and geopolitical dynamics. ABOUT THE SERIES Matters of Policy & Politics, a podcast from the Hoover Institution, examines the direction of federal, state, and local leadership and elections, with an occasional examination of national security and geopolitical concerns, all featuring insightful analysis provided by Hoover Institution scholars and guests. To join our newsletter and be the first to tune into the next episode, visit Matters of Policy & Politics.

Technology in hunting is advancing faster than most of us can keep up with. Thermals. Night vision. Cell trail cameras. Drones. AI filtering game cam photos. The Idaho Hunting and Advanced Technology Working Group (here) spent months wrestling with one big question: at what point does modern advantage overwhelm wildlife and erode fair chase? In this episode, Idahoans Tal Sampson and Brock Maynard break down what the Hunting and Technology (H.A.T.) Working Group actually did, what proposals are heading to the Idaho Legislature, and why this is not a “ban” but a proposed prohibited timeframe from August 30 through December 31 for certain high-tech tools. We talk real harvest data, opportunity vs. limited hunting, predator management carve-outs, long-range shooting, and the uncomfortable truth that hunters are the minority voice in today's culture. Whether you agree or disagree, this conversation matters for the future of hunting across the West. If you care about opportunity, the sustainability of hunting, and fair chase ethics, now is the time to get informed and get involved ahead of the 2026 Idaho Legislative Session.  Enjoy this episode of the Rokcast!  You can read other Rokslide articles, see videos, and listent to Rokcast episodes here

Hour 2 opens talking about the United States men's and women's hockey teams winning the gold medal over archrival Canada and the special moments immediately after the victories. Ku dives deep into the analysis of last week's Tourism and Gaming Working Group meeting that discussed the pros and cons of bringing legal gaming and gambling to Hawai'i with special guest Bo Bernhard. You can catch the recording of this episode on our YouTube channel, Hawaii Sports Radio Network.

Happy Aloha Friday, beautiful people! Ku & Paul run through a rapid recap of a packed Thursday that saw a ton of winning from HPU and UH programs, including the first victory in the career of new Hawaii beach volleyball HC Danny Alvarez. We hear from Hawaii HC Rich Hill & hero from Thursday night Kody Watanabe after the BaseBows came back to stun the Wichita State Shockers with seven runs in the late innings to kick of Les Murakami weekend with a bang. The first hour wraps up talking about yesterday's Tourism & Gaming Working Group hearing with gaming expert/UNLV professor Dr. Bo Bernhard and the confusion around the potential impact changes to the gaming industry in Hawai'i could have. Watch the hearing HERE.

The Hoover Applied History Working Group hosted its virtual Winter 2026 Symposium on Thursday, February 12, 2026, 8:00 a.m. - 6:00 p.m. Pacific Time.  The Symposium theme is “America and the World at 250.” As the United States begins to celebrate the nation's 250th anniversary, our intention is to review recent historiographical developments, revisit enduring debates, spark new ones, and relate them to contemporary world order and the crises facing America at home and abroad. 

Host Joe DeMare takes a minute to say "I told you so!" over the recent realization by many climate scientists that the globe is caught in a global warming positive feedback loop. In other words, the effect of warming is to cause more warming at an accelerating rate. Systems caught in feedback loops continue to accelerate until they tear themselves apart. Joe has been saying this for more than 25 years. Next, he counters that with an interview with Lynda Williams. Ms. Williams was on a Working Group for the state of Hawai'i that recently rejected nuclear power. Included is her hard rock song, "Depleted Uranium." Rebecca Wood talks about the Rapahannock River. Ecological News includes an HB6 update including a court case that could make bribery legal, a biological control approved for garlic mustard, and the elimination of the endangerment finding.#FAGF #ForAGreenFuture #hawai'i #nuclear #unplug #environmentalnews #nonuclear   

SummaryThis Uromigos podcast delves into the evolution and significance of the Prostate Cancer Working Group criteria, highlighting the iterative process of developing guidelines that reflect the latest scientific evidence and clinical practices. The speakers discuss the new PCWG4 including new nomenclature, the role of imaging technologies like PSMA PET, and the importance of biomarkers and patient-reported outcomes in enhancing patient care and treatment efficacy. They emphasize the collaborative nature of the working groups and the ongoing need for adaptation in response to emerging data and technologies.

Host Dr. Davide Soldato and guests Dr. David Einstein and Dr. Ravi Madan discuss JCO article, "National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations," underscoring the need for a consensus on clinical trial designs implementing novel endpoints in this population, the importance of PSA doubling time as a prognostic factor and with an emphasis on treatment de-escalation to limit toxicity and improve patient outcomes. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO authors Dr. David Einstein and Dr. Ravi Madan. Dr. Einstein is a medical oncologist specializing in genitourinary malignancy working at Beth Israel Deaconess Medical Center, part of the DFCI Cancer Center, and an assistant professor at Harvard Medical School. Dr. Madan is a senior clinician at the National Cancer Institute (NCI), where he focuses on conducting clinical research in prostate cancer, particularly in the field of immunotherapy. Today, we will be discussing the article titled, "National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations." So, thank you for speaking with us, Dr. Einstein and Dr. Madan. David Einstein: Thanks for having us. This is a great pleasure. Ravi Madan: Appreciate being here. Davide Soldato: So, I just want to start from a very wide angle. And the main question is why did you feel that there was the need to convey a consensus and a working group to talk about this specific topic: biochemically recurrent prostate cancer? What has been the change in current clinical practice and in the trial design that we are seeing nowadays? And so, why was it necessary to convey such a consensus and provide considerations on novel clinical trials? David Einstein: Yeah, so I think it's very interesting, this disease state of biochemically recurrent prostate cancer. It's very different from other disease states in prostate cancer, and we felt that there was a real need to define those differences in clinical trials. Years ago, metastatic castration-resistant prostate cancer was the primary disease state that was explored, and over time, a lot of things shifted earlier to metastatic disease defined on a CAT scan and bone scan to an earlier disease state of metastatic castration-sensitive prostate cancer. And the clinical trial principles from late-stage could be applied to MCSPC as well. However, BCR is very different because the patients are very different. And for those reasons, there are unique considerations, especially in terms of toxicity and treatment intensity, that should be applied to biochemically recurrent prostate cancer as opposed to just using the principles that are used in other disease states. And for that reason, we thought it was very important to delineate some of these considerations in this paper with a group of experts. Davide Soldato: Thanks so much. So, one of the main changes that have been applied in recent years in clinical practice when looking at biochemically recurrent prostate cancer is the use of molecular imaging and particularly of PSMA PET. So, first of all, just a quick question: was the topic of the consensus related on which threshold of PSA to use to order a PET scan to evaluate this kind of patient? David Einstein: Yeah, thanks for that question. It's a super important one. The brief answer is that no, we did not address questions about exactly when clinicians would decide to order scans. We were more concerned with the results of those scans in how you define different disease states. But I think as a broader question, I think a lot of folks feel that finding things on a scan equates that with what we used to find on conventional scans. And fundamentally, we actually sought to redefine that disease space as something that's not equivalent to metastatic disease, and rather coined the term "PSMA-positive BCR" to indicate that traditional BCR prognostic criteria and factors still apply, and that these patients have a distinct natural history from those with more advanced metastatic disease. Ravi Madan: And if I may just add that the National Cancer Institute is running a trial where we're prospectively monitoring PSMA-positive BCR patients. And that data is clearly showing that, much like what we knew about BCR a decade ago, PSMA findings in BCR patients do not change the fact that overall, BCR is an indolent disease state. And the findings, which are usually comprised of five- to seven-millimeter lymph nodes, do not endanger patients or require immediate therapy. And so, while PSMA is a tool that we can be using in this disease state, it doesn't really change the principal approach to how we should manage these patients. And as Dr. Einstein alluded to, there is a drive to create a false equivalency between PSMA-positive BCR and metastatic castration-sensitive prostate cancer, but that is not supported by the data we're accumulating or any of the clinical data as it exists. Davide Soldato: One thing that it's very important and you mentioned in your answer to my question was actually the role of PET scan and conventional imaging, so CAT scan and bone scan that we have used for years to stage patients with metastatic prostate cancer. And you mentioned that there is a distinction among patients who have a positive PET scan and a BCR, and patients who have a positive conventional imaging. And yet, we know that sometimes the findings of the PET scan are not always so clear to interpret. So, I just wanted to understand if the consensus reached an agreement as to when to use conventional imaging to potentially resolve some findings that we have on PET scan among thess patients with BCR? David Einstein: Yeah, I think there's a number of questions actually buried within that question. One of which is: does PSMA PET result in false positives? And the answer has definitely been yes. There's a known issue with false-positive rib lesions. And so, first and foremost, we need to be very careful in calling what truly is suspicious disease and what might actually not be cancer or might be something that is totally separate. So I think that's the first part of the answer to that question. The second is to what extent do we need to use paired PET and conventional imaging to define this disease state? In other words, do you have to have positive findings on one and negative findings on the other in order to enter this definition? The challenge there, as we discussed, is that logistically, oftentimes it's hard to get patients to do multiple sets of scans to actually create that definition. Sometimes it's difficult to get insurers to pay for such scans. And finally, it's hard to sometimes blind radiologists to the results of one scan in reading the other. So, we did have some deliberations about to what extent you could use some of the CAT scan portion of a PSMA PET in order to at least partially define that. We also talked about using bone scans to confirm any bone findings seen on PET. But I think another important part of this is not just the baseline imaging, but also what's going to be done serially on a study in order to define responses and progression. And that's sort of a whole separate conversation about to what extent you can interpret changes in serial PET. Ravi Madan: And just to pick up on the key factor here, I think that the PSMA PET in BCR is pretty good at defining lymph node disease, and that's actually predominantly 80 to 90 percent of the disease seen on these findings. It might be pretty good at also defining other soft tissue findings. The real issues come to bone findings. And one thing the group did not feel was appropriate was to just define only PSMA-positive bone findings confirmed on a CT bone window. There's not really great data on that, but the working group felt that, when in the rare situation, because it is relatively rare, a PSMA-positive finding is in a bone, a bone scan should be done. And it's worth noting that Phu Tran, who is a co-author and a co-leader of this working group, his group has already defined that underlying genomics of conventionally based lesions, such as bone scan, are more aggressive than findings on next-gen imaging, such as PSMA. So, there is also a genomic underlying rationale for defining the difference between what is seen on a PET scan in a bone and what is seen on a bone scan. Davide Soldato: Coming back to this issue of PET PSMA sometimes identifying very small lesions where we don't see any kind of correlates on conventional imaging or where we see only very little alteration on the bone scan or in the CT scan, was there any role that was imagined, for example, for MRI to distinguish this type of findings on the PET scan? Ravi Madan: So, I think that, again, what can be identified on a PSMA frequently cannot be seen on conventional imaging. We didn't feel that it was a requirement to get an MRI or a CT to necessarily confirm the PSMA findings. I think that generally, we have to realize that in this disease state, that questionable lesions are going to be seen on any imaging, including PSMA. We've actually probably put way too much faith in PSMA findings thus far, as Dr. Einstein alluded to with some of the false positives we're seeing. So, I think that these false positives are going to have to be baked into trials. And in terms of clinical practice, it highlights the need to again, not overreact to everything we see and not necessarily need to biopsy everything and put patients' health in jeopardy to delineate a disease that's indolent anyway. Davide Soldato: Thanks so much. That was very clear. So, basically, the main driver was really also the data showing that if we have a BCR, so a patient with a biochemically recurrent disease that is positive on the conventional imaging, this is usually associated with a different aggressiveness of the disease. But coming back to a comment that you made before, Dr. Madan, you said that even if we talk about PSMA-positive BCR, we are still talking about BCR and the same criteria should apply. So, what we have used for years in this space to actually try to stratify the prognosis of patients is the PSA doubling time, so how quickly the PSA rises over time. So, coming back to that comment, was the consensus on the PSA doubling time basically retained as what we were using before, so defining patients with a doubling time less than 12 months, 10 months, 9 months, as patients with a higher risk of progressing in terms of developing metastatic disease? Ravi Madan: Yes, so that's a very important point. And the working group defined high-risk BCR as a PSA doubling time less than six months. And this really comes from Johns Hopkins historical data, which shows that if your doubling time is three months or less, there's about a 67 percent chance of metastasis at five years. If it's between three and six months, it's 50 percent. And if it's over six months, if it's between six and nine months, it's roughly only 27 percent. There are trials that are accruing with eligibility criteria that they may describe as high-risk that are beyond six months, but the data as really it's been defined in the literature highlights that truly high-risk BCR is less than six months. And the working group had a consensus on that opinion, and that was our recommendation. David Einstein: And I think an important follow-on to that is that's regardless of PET findings, right? And so, we present a couple of case studies of patients with positive PET findings who have a long doubling time, in whom the disease is in fact indolent, as you would have expected from a traditional BCR prognostic standpoint. Obviously, there are patients in whom they have fast doubling times, and even if they do not have PET findings, that doesn't make them not high-risk. Ravi Madan: And just to follow up that point, I will let you know a little bit of a free preview that my colleague Melissa Abel from the NCI will be presenting PSMA findings in the context of PSA doubling time at ASCO GU if that data is accepted. Davide Soldato: Looking forward for those data because I think that they're going to clarify a lot of the findings that we have in this specific population. And coming back to one of the points that we made before, so PET PSMA has a very high ability to discriminate also a very low burden of disease, which we currently refer to as oligometastatic biochemically recurrent prostate cancer, which is not entirely defined as an entity. But what we are seeing both in some clinical trials, which use mainly conventional imaging, but also what we're starting to see in clinical practice, is that frequently we use the metastasis-directed therapy to treat these patients. So, just a little bit of a comment on the use of this type of strategy in clinical practice and if the panel thought of including this as, for example, a stratification criteria or mandated in the design of novel clinical trials in the field of BCR? David Einstein: Yeah, I think that's an incredibly important point. You know, fundamentally, there's a lot of heterogeneity in practice where some folks are using local salvage approaches, some are using systemic therapies, in some cases surveillance may be reasonable, or some combination of these different strategies. We certainly have phase two data from multiple trials suggesting that met-directed therapy may help buy patients time off of treatment until subsequent treatments are started. And that in and of itself may be an important goal that we can come back to in discussing novel endpoints. I think what our panel acknowledged was that, in some sense, the clinical practice has gotten even farther ahead than where the data are, and this is being offered pretty routinely to patients in practice. And so, what became clear was that we, in developing clinical trials, cannot forbid investigators from doing something that would be within their usual standard of care, even if it might not be supported by the most robust data. But at minimum, it definitely should be used as a stratification factor, or in some trial designs, you can do met-directed therapy after a primary endpoint is assessed. And that offers a compromise between testing, say, the effect of a systemic therapy but also not excluding patients and investigators from doing what they would have done had they not been on a study. Ravi Madan: And I would just like to follow up your phrasing in the question of "oligometastatic prostate cancer." We have a figure in the paper and it highlights the fact that, unfortunately, that term in prostate cancer is imaging agnostic. And we've already discussed in this podcast, as well as in the paper, that imaging used to define a metastatic lesion, whether it's PSMA or conventional imaging, carries with it a different clinical weight and a different prognosis. So, we feel in the working group, that the correct term for this disease state of PSMA-positive BCR is just that: PSMA-positive BCR. We also have to realize that when we talk about oligometastatic disease, while it's imaging agnostic, it seems to be numerically based, whether it's five or three or 10 depending on the trial. But PSMA-positive BCR does not have a limit in terms of the number of lesions. And so again, we just feel that there is an important need to delineate what we're seeing in this disease state, which again is PSMA-positive BCR, and that should be differentiated frankly from oligometastatic disease defined on other imaging platforms. David Einstein: Right, and that also makes clear that patients can have polyfocal disease on PET that still is not what we would consider metastatic, but goes beyond the traditional definition of oligometastatic. So, in other words, just because someone has PET-detected disease only, that does not automatically equate with oligometastatic. Davide Soldato: Thanks so much. So, you were speaking a little bit, Dr. Einstein, about the different types of treatment that we can propose or not propose to this patient because you mentioned, for example, that in clinical practice MDT, so metastasis-directed therapy, is becoming more and more used. For these patients, we can potentially use systemic treatments, which include androgen deprivation therapy, which can be given continuously or in an intermittent fashion. And recently, we can also use novel systemic therapies, for example, enzalutamide, to treat this type of patient. So, given that the point of the consensus was really to provide consideration for novel clinical trials in this space, what was the opinion on the panel regarding the control arm? So, if we're looking at a novel therapy in the BCR space, does the control arm need to include a therapy or not? And if so, which therapy? David Einstein: Yeah, this is a super important question and one that's subject to a lot of discussion, especially in light of recent data from EMBARK. What we came to a consensus around was the fact that neither MDT nor systemic therapy should be required as a control arm on BCR trials. And we can talk about a number of reasons for that. There's also the pragmatics of what investigators might actually accrue patients to and what they would consider their standard of care, and that's important to factor in, too. I think that one of the major goals of our working group was outlining what kinds of trials we would like to see in the future and where the limitations of the current data stand. For example, EMBARK proposes a strategy of a single treatment discontinuation and resumption at a predefined threshold indefinitely. That's probably not how most people are practicing. Most folks are probably using some version of intermittent therapy as they would have before this trial, but we actually don't have any data supporting that. Moreover, we don't have data comparing different intermittent strategies to one another. We don't know what the right thresholds are, we don't know how much time we buy patients off treatment, and we don't know to what extent MDT modifies that. And so, those are all really important questions to be asking in future versions of these trials. I'd say my second point would be that a lot of drug development is happening with novel therapies that are not hormonal, trying to bring them into this space. And when you think about trying to compare one of those types of therapies to a hormonal therapy on short-term endpoints, the hormonal therapy is always going to win. Hormonal therapy is almost universally effective, it will bring down PSAs, and it will prolong, quote-unquote, "progression." The downside of that is that hormonal therapy doesn't actually modify the disease, it suppresses it, and it tends to have fairly transient effects once you remove it. And so, part of our goal was in trying to figure out some novel endpoints that would allow these novel types of therapies to be examined head-to-head against a more traditional type of hormonal therapy and have some measurement of some of the more long-term impacts. Davide Soldato: So, jumping right into the endpoints, because this is a very relevant and I think very well-constructed part of the paper that you published. Because in the past we have used some of these endpoints, for example, metastasis-free survival, as potentially a proxy for long-term outcomes. But is this the right endpoint to be using right now, especially considering that frequently this outcome is measured using conventional imaging, but we are including in these trials patients who are actually negative on conventional imaging but have a positive PSMA when they enter this type of trial? David Einstein: Yeah, there's a number of challenges with those types of endpoints. One of which is, as you say, we're changing the goalposts a little bit on how we're calling progression. We still don't exactly understand what progression on PET means, and so that's something that is challenging. That said, we're also cognizant of the fact that many times investigators are likely to get PET scans in the setting of rising PSA, and that's going to affect any endpoint that relies purely on conventional imaging. So, there's some tension there between these two different sets of goalposts. One thing that we emphasize is that not only are there some challenges in defining those, but also there're challenges in what matters to a patient. So, if a progression event occurs in the form of a single lesion on a PET scan or even a conventional image, that might be relevant for a clinical trial but might be less relevant for a patient. In other words, that's something that, in the real world, an investigator might use serial rounds of metastasis-directed therapy or intermittent therapy to treat in a way that doesn't have any clinical consequences for the patient necessarily. In other words, they're asymptomatic, it's not the equivalent of a metastatic castration-resistant disease progressing. And so, we also need to be cognizant of the fact that if we choose a single endpoint like PFS, that there's going to be many different versions of progression, some of which probably matter clinically more than others, and some of which are more salvageable by local therapies than others. Ravi Madan: So I think the working group really thoughtfully looked at the different options and underscored perhaps strengths and weaknesses, and I think that's presented as you mentioned in the paper. But I think it's also going to depend on the modality, the approach of the therapeutic intervention. In some cases if it's hormone-based, then maybe PSA is providing some early metrics, maybe metastasis-free survival is more relevant in a continuous therapy, but intermittent therapies might have a different approach. There's emerging immunotherapy strategies, radiopharmaceutical strategies, they might have some more novel strategies as well. I think we have to be open-minded here, but we also have to be very clear: we do not know what progression is on a PSMA scan. Just new lesions may not carry the clinical significance that we think, and we may not know what threshold that ultimately becomes clinically relevant is. So, I do think that there was some caution issued by the working group about using PSMA as an endpoint because we still do not have the data to understand what that modality is telling us. Again, I'm optimistic that the National Cancer Institute's prospective data set that we've been collecting, which has over 130 patients now, will provide some insights in the months and years ahead. Davide Soldato: So, just to ask the question very abruptly, what would you feel like the best endpoint for this type of trials is? I understand that is a little bit related to the type of treatments that we're going to use, whether it's intermittent, whether it's continuous, but do we have something that can encapsulate all of the discussion that we have up until this point? David Einstein: Yeah, so that's a perfect segue to the idea of novel endpoints, which we feel are very important to develop in these novel disease spaces. So, one thing that we discussed was an endpoint called treatment-free survival, which conceptually you can think of as exactly what it sounds like, but statistically you actually have to do some work to get there. And so essentially, you imagine a series of Kaplan-Meier curves overlaid: one about overall survival, one time to next therapy, one time on initial therapy. You can actually then take the area under those curves or between those curves and essentially sum it up using restricted mean survival time analysis. And that can give you a guide about the longitudinal experience of a patient: time spent on treatment versus off treatment; time spent with toxicity versus without toxicity. And importantly, each one of those time-to-event metrics can be adjusted depending on exactly what the protocol is and what is allowed or not allowed and what's prespecified as far as initiation of subsequent therapies. So, we felt that this was a really important endpoint to develop in this disease space because it can really capture that longitudinal aspect. It can really reward treatments that are effective in getting durable responses and getting patients off of therapy, because unfortunately, PFS-based endpoints generally reward more or longer systemic therapy versus shorter or no systemic therapy, and that's sort of an artificial bias in the way those endpoints are constructed. So, I think that there are challenges of course in implementing any new endpoint, and some of the things that are really critical are collecting data about toxicity and about subsequent therapies beyond what a typical trial might collect. But I think in this kind of disease space, that longitudinal aspect is critical because these are really patients who are going to be going through multiple rounds of therapy, going to be going on and off treatments, they're going to be using combinations of local and systemic therapies. And so, any one single endpoint is going to be limited, but I think that really highlights the limitations of using PFS-based endpoints in this space. Ravi Madan: I also think that in the concept of treatment-free survival lies one of the more powerful and, honestly, I was surprised by this, that it was so universally accepted, recommendations from the committee. And that was that the general approach to trials in this space should be a de-escalation of the EMBARK strategy as it's laid out with relatively continuous therapy with one pause. And so, I think again, buried in all of this highlights the need for novel endpoints like treatment-free survival. We get to the fact that these are patients who are not at near-term clinical risk from symptoms of their disease, so de-escalating therapies does not put them at risk. And if you look at, for example, lower-volume metastatic castration-sensitive prostate cancer, it's become realized that we need to de-escalate, and there are now trials being done to look at that. Historically, we know that BCR is an indolent disease process for the vast majority of patients who are not at near-term risk from clinical deterioration. So, therefore, we shouldn't wait a decade into abundant BCR trials to de-escalate. The de-escalation strategy should be from the outset. And that was something the committee really actually universally agreed on. David Einstein: And that de-escalation can really take multiple forms. That could be different strategies for intermittent therapy, different start-stop strategies. It could also mean actually intensifying in the short-term with the goal long-term de-intensification, kind of analogous to kidney cancer where we might use dual checkpoint inhibitors up front with some higher upfront toxicity but with the hope of actually long-term benefit and actually being able to come off treatment and stay in remission. Those kinds of trade-offs are the types of things that are challenging to talk about. There's not a one-size-fits-all answer for every patient. And so, that's why some of these endpoints like treatment-free survival would be really helpful in actually quantifying those trade-offs and allowing each patient to make decisions that are concordant with their own wishes. Davide Soldato: Thanks so much. That was very clear, especially on the part of de-escalation, because, as you were mentioning, I think that we are globally talking about a situation, a clinical situation, where the prognosis can be very good and patients can stay off treatment for a very long period of time without compromising long-term outcomes. And I think that well-constructed de-escalation trials, as you were mentioning and as the consensus endorsed, are really needed in this space also to limit toxicity. This brings us to the end of this episode. So, I would like to thank again Dr. Einstein and Dr. Madan for joining us today. David Einstein: We really appreciate the time and the thought, and I think that even starting these types of discussions is critical. Even just recognizing that this is a unique space is the beginning of the conversation. Ravi Madan: Yeah, and I want to thank JCO for giving us this forum and the opportunity to publish these results and all the expert prostate cancer investigators who were part of this committee. We produced some good thoughts for the future. Davide Soldato: We appreciate you sharing more on your JCO article titled, "National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinion of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Learn more about your ad choices. Visit megaphone.fm/adchoices

President Donald Trump is frustrated with Department of Justice officials tasked with reviewing “politicized justice.” The House is preparing to vote on a deal aimed at averting a full government shutdown. Target's new CEO is stepping in as the company navigates economic and political strain. The US and Iran are working toward a new nuclear deal.  Plus, police and rescue teams are searching for the mother of an NBC "Today" anchor Learn more about your ad choices. Visit podcastchoices.com/adchoices

Guest: Mariam Wahba. Wahba from the Foundation for Defense of Democracies reports on the persecution of Christians in Nigeria by jihadists and Fulani militants. She details a newly established White House working group designed to help the Nigerian government fix security gaps and enforce laws against the perpetrators of this religiously motivated violence.1900 ISTANBUL

Hour 2 gets into the local government discussion after the new Hawai'i Tourism & Gaming Working Group met for the first time and discussed gaming regulation in the islands. Ku & Paul give their takes after playing snippets from Mike Lambert and Gregorr Illagan from the Thursday meeting. We wrap up the day talking more NFL Coaching Carousel as the Bills look for a new HC with interviews of Brian Daboll, Joe Brady & Phillip Rivers.

Brazil's Space Sector: 2025 Shifts and Future OutlookIn this episode of Space Cafe Radio, host Torsten Kriening sits down with Ian Grosner, the Head of the Legal Department of the Brazilian Space Agency, Chair of the Working Group on the Definition and Delimitation of Outer Space of COPUOS, Chair of the Latin American and Caribbean Subcommittee (LAC-SC) of the IAF to discuss the significant shifts in Brazil and Latin America's space sector in 2025. Ian provides insights on how the industry has transitioned from a technology-driven model to a market-oriented approach, emphasizing the essential role of satellites in agriculture, climate policy, and security. They also talk about the educational impact of small satellite programs, Brazil's progress with the Alcântara launch site, and the challenges faced by the burgeoning space startup ecosystem. Join us as we explore how Brazil is integrating space-based data to drive economic and strategic outcomes on Earth.Space Café Radio brings you talks, interviews, and reports from the team of SpaceWatchers while out on the road. Each episode has a specific topic, unique content, and a personal touch. Enjoy the show, and let us know your thoughts at radio@spacewatch.globalWe love to hear from you. Send us your thought, comments, suggestions, love lettersSupport the showYou can find us on: Spotify and Apple Podcast!Please visit us at SpaceWatch.Global, subscribe to our newsletters. Follow us on LinkedIn and X!

Welcome back to PING for 2026 and season 6. This time on PING, we have a pair of interviews with students from the National Institute of Technology Karnataka, Surathkal (NITK), recorded last year at IETF 122. This is the second time we've heard from students from NITK. We previously heard from Vanessa Fernandes and Kavya Bhat when they attended IETF 119 in 2024. NITK is a large, technically focused university located on India's south-western coast in the state of Karnataka. The state is home to major technology hubs, such as Bengaluru and Mangaluru, alongside institutions like NITK, which play a key role in developing technical talent. Against this backdrop, it is unsurprising that NITK students show a strong interest in network technologies and Internet protocol development. Dr Mohit Tahiliani, Associate Professor at NITK, has led a multi-year program involving undergraduate, postgraduate, and postdoctoral researchers to engage with emerging Internet standards. Through this program, participants explore new ideas, contribute code, and take part in IETF hackathons and Working Group activities. This work has been supported in part by the APNIC Foundation. Last time with Vanessa and Kavya, we explored NITK's multi-year campus IPv6 deployment, which has been underway for some time. That work has included direct engagement with the IETF, with Dr Mohit Tahiliani's students attending alongside Nalini Eklins, who is involved both in the IPv6 deployment at NITK and in IPv6 standards work within the IETF. Since then, both students have gone on to work in networking roles or to pursue further study, reflecting the longer-term impact of sustained involvement in operational and standards-based Internet engineering. This time, we've got two different projects and NINE students to hear from. The first group is Rati Preethi Subramanian, Shriya Anil, Mahati Kalale, Anuhya Murki and Supradha Bhat, who explored fair queuing disciplines, FQ_Codel, a derivative FQ_Codel++ and a new proposed model, FQ_Pie. They worked with the NS3 network simulator and CCPerf, exploring how these queueing disciplines compare, and discussed their project with me at IETF 122. The second group are Vartika T Rao, Hayyan Arshad, Siddharth Bhat and Bharadwaja Meherrushi Chittapragada, who looked at the YANG data model in the network management space, and more efficient ways to manage data coming out of networking systems using YANG. They wrote a producer-consumer model in Python code, and explored time-series databases using interface packet count collections as an example YANG dataset to explore, in the CBOR encoding. Finally, I spoke with Dr Mohit Tahiliani, who has been leading this project. He is strongly committed to bringing new and younger voices into IETF work, recognizing the value of exposing students to real-world protocol development early in their careers. This experience benefits participants by grounding their learning in practical standards work, while also helping the IETF engage with new contributors who may return to protocol development in the future. This sustained engagement has already had tangible outcomes: The students involved have gone on to roles in the ICT sector or to further academic study, demonstrating the long-term value of this collaborative model.

Today my guest is Renuka Sane who is the managing director of Managing Director of Trustbridge. An institution that seeks to improve India's business environment by improving the rule of law. Renuka was a member of many expert committees including: the Task Force of Experts set up by the Employees Provident Fund Organisation; the research team of the Bankruptcy Legislative Reforms Commission; the Pension Advisory Committee of the Pension Fund Regulatory Development Authority; and the Working Group on personal insolvency at the Insolvency and Bankruptcy Board of India. She received a Ph.D. in Economics from the University of New South Wales.  We talked about the old, new, and unified pension scheme and related reforms over the last few decades in India, India's broader financial regulation framework, separation of powers in regulatory authorities, the way regulatory orders are written, and much more.  Recorded December 17th, 2025. Read a full transcript enhanced with helpful links. Learn more about The 1991 Fellowship. Connect with Ideas of India Follow us on X Follow Shruti on X Follow Renuka on X Click here for the latest Ideas of India episodes sent straight to your inbox. Timestamps (00:00:00) - The 1991 Fellowship (00:01:09) - Intro (00:02:49) - India's Pension System (00:35:42) - Private Sector Pension Schemes (01:06:28) - Regulatory Orders (01:24:03) - Improving Transparency at the Reserve Bank of India (01:34:57) - Outro  

When countries can commit genocide or invade neighbours with few repercussions, it's clear that international norms and laws are not working. On the podcast, three legal experts discuss the problems and some steps forward, from decentralised ways of enforcing criminal law, to including non-state actors, to erasing the legal loopholes used to justify violence. Guests:  Neve Gordon, professor of international law and human rights at Queen Mary University of London and a fellow of the British Academy of Social Sciences. He has written extensively about the Israeli–Palestinian conflict, the bombing of healthcare facilities, and coined the term "medical lawfare." Oona Hathaway, professor of international law at Yale Law School who has been a member of the Advisory Committee on International Law for the legal adviser at the US Department of State since 2005 and a member of the Council on Foreign Relations since 2011. She is working on a book titled "War Unbound: Gaza, Ukraine, and the Breakdown of International Law". Michael Addo, law professor at the University of Notre Dame and lawyer with expertise in international human rights law and international business policy. The UN Human Rights Council appointed him in 2011 to join its Working Group on Business and Human Rights, which he currently chairs. Got a question or feedback? Email podcast@thenewhumanitarian.org or post on social media using the hashtag #RethinkingHumanitarianism.

A video of this podcast is available on YouTube, Spotify, or PwC's website at viewpoint.pwc.comThe GHG Protocol has released its long-awaited proposed updates to the Scope 2 Guidance. In this episode, we highlight the key changes in the exposure draft, including proposed revisions to location-based and market-based reporting, hourly matching, emission factor hierarchies, and more. We also explore what these developments could mean for companies and how stakeholders can participate in the revision process.In this episode, we discuss:2:49 – Redefining the purpose for location-based and market-based reporting5:33 – The importance of the decision-making criteria6:56 – New emission factor hierarchy for location-based reporting14:30 – Shift toward hourly matching in the market-based method21:53 – Deliverability criteria and implications for renewable energy credits26:19 – Residual mix and fossil-only defaults for unclaimed energy32:45 – How companies can share feedback and next steps for the Scope 2 guidanceFor more on the GHG Protocol's exposure draft, see our publication, GHG Protocol announces Scope 2 Public Consultation, which was updated to indicate that the public consultation deadline was extended to January 31, 2026.Check out our previous episodes for more on the GHG Protocol and GHG reporting:Sustainability now: Modernizing the GHG ProtocolSustainability now: Inside the GHG Protocol's scope 3 updateSustainability now: GHG reporting trends and challengesLooking for the latest developments in sustainability reporting? Follow this podcast on your favorite podcast app and subscribe to our weekly newsletter to stay in the loop for the latest thought leadership on sustainability standards. About our guestColin Powell is PwC Canada's Technical Net Zero Leader. His work focuses on GHG quantification, life cycle assessment, target setting, and decarbonization strategies. He has helped companies measure over 1 billion tonnes of emissions and previously worked as a consultant supporting global clients in decarbonization. Colin sits on the GHG Protocol's Scope 3 Working Group, helping shape updates to global standards. He is also a Professional Engineer (Ontario) with a PhD in wastewater treatment modeling.About our hostHeather Hornis the PwC National Office Sustainability and Thought Leader, responsible for developing our communications strategy and conveying firm positions on accounting, financial reporting, and sustainability matters. In addition, she is part of PwC's global sustainability leadership team, developing interpretive guidance and consulting with companies as they transition from voluntary to mandatory sustainability reporting.Transcripts available upon request for individuals who may need a disability-related accommodation. Please send requests to us_podcast@pwc.comDid you enjoy this episode? Text us your thoughts and be sure to include the episode name.

Amy MacIver is joined by Veda Pretorius, the driving force behind Superyacht Cape Town and the Southern Africa Superyacht Route working group, to unpack how this route is being shaped and what it could mean for coastal communities, tourism, and the marine economy. Presenter John Maytham is an actor and author-turned-talk radio veteran and seasoned journalist. His show serves a round-up of local and international news coupled with the latest in business, sport, traffic and weather. The host’s eclectic interests mean the program often surprises the audience with intriguing book reviews and inspiring interviews profiling artists. A daily highlight is Rapid Fire, just after 5:30pm. CapeTalk fans call in, to stump the presenter with their general knowledge questions. Another firm favourite is the humorous Thursday crossing with award-winning journalist Rebecca Davis, called “Plan B”. Thank you for listening to a podcast from Afternoon Drive with John Maytham Listen live on Primedia+ weekdays from 15:00 and 18:00 (SA Time) to Afternoon Drive with John Maytham broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/BSFy4Cn or find all the catch-up podcasts here https://buff.ly/n8nWt4x Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Speaker: Susie Becher, Communications Director, Policy Working Group (PWG)*Hosted by the Britain Palestine ProjectIn this wide-ranging and deeply insightful conversation, Susie Becher — Communications Director of the Policy Working Group (PWG), founding member of All Its Citizens, managing editor of the Palestine-Israel Journal, longtime activist, and former US Embassy analyst — explores the state of the Israeli-Palestinian conflict, the failures of diplomacy, and the urgent need for international engagement to secure a just two-state solution.Susie reflects on her 50 years in Israel, her work across civil society and political organisations, and the motivations guiding the PWG's advocacy. She gives a candid, nuanced analysis of Israeli politics, the post-October 7th reality, and the dangers posed by current geopolitical dynamics — including the US administration's shifting policies and the rise of anti-democratic tendencies within Israel.A central highlight of the webinar is Susie's detailed account of the PWG's recent advocacy trip to the UK, where they met with parliamentarians, Foreign Office officials, think tanks, civil society actors, and Middle East analysts to discuss recognition of Palestine, protecting international law, and countering the growing marginalisation of the two-state solution.

Today we are talking about the community working group, What they do, and how you can help with guests AmyJune Hineline, Mark Casias, and Matthew Saunders. We'll also cover Drupal CMS Geo Images as our module of the week. For show notes visit: https://www.talkingDrupal.com/530 Topics Exploring the Community Working Group (CWG) Roles and Responsibilities within the CWG Conflict Resolution and Community Health Matthew's Journey and Joining the CWG Qualities and Experiences for CWG Members Identifying the Need for Cultural Sensitivity The Importance of Patience and Grace in Conflict Resolution Onboarding and the Role of the Community Health Team Time Commitment and Responsibilities of CWG Members Supporting the CWG Without Formal Membership Maintaining Confidentiality and Promoting Transparency Addressing Credit Abuse and Community Health Parting Words of Wisdom for Aspiring Community Members Resources Recipe application Guests AmyJune Hineline - volkswagenchick Matthew Saunders - jamesmatthewsaunders.ai MatthewS Mark Casias - omibee.com markie Hosts Nic Laflin - nLighteneddevelopment.com nicxvan John Picozzi - epam.com johnpicozzi MOTW Correspondent Mike Anello - drupaleasy.com ultimike Brief description: Drupal CMS Geo Images - a Drupal CMS recipe that automatically displays uploaded geotagged images on a map. Module name/project name: Drupal CMS Geo Images Brief history How old: created in February 2025 by Italo Mairo (https://www.drupal.org/u/itamair). He is also one of the maintainers of the GeoField module as well as many of the other geo-spatial related contrib modules. Versions available: 1.1.4, released Nov 9 2025. Maintainership Actively maintained Security coverage Documentation - yes, on the project page (README is the same) Number of open issues: 1 open issues, 0 of which are bugs against the current branch (2 total issues) Module features and usage Creates new "Geo image" media type Displays image and map Bulk import via Media Library Importer module Includes preconfigured map view (filterable by date) Each mapped photo displayed with image thumbnail on map

Greenhouse gas (GHG) reporting continues to evolve, with companies facing increasing complexity in navigating frameworks, data quality, and materiality. In this episode, we explore recurring themes and practical challenges in GHG disclosures—from organizational boundaries to the role of renewable energy credits (RECs)—with insights from our specialists deeply engaged in global sustainability reporting.In this episode, we discuss:1:22 – GHG reporting landscape and regulatory shifts5:01 – Materiality, alignment with financial reporting, and minimum boundaries23:48 – Organizational boundaries and key decisions companies are facing31:35 – Scope 2 renewable energy certificates: timing, location, and use43:00 – Systems, tools, and data quality, including preparing for reporting and assuranceLooking for more on GHG and sustainability reporting?Sustainability now: Inside the GHG Protocol's scope 3 updateSustainability now: A primer on California climate reportingOther episodes in our sustainability reporting podcast seriesGHG Protocol announces Scope 2 Public ConsultationPwC's Sustainability reporting guideBe sure to follow this podcast on your favorite podcast app and subscribe to our weekly newsletter to stay in the loop for the latest thought leadership on sustainability reporting.About our guestsMarcin Olewinski is a PwC Assurance practice partner with over 20 years of experience bringing valued perspectives and insights to large clients in the energy sector. Additionally, he's focused extensively within the National Office on greenhouse gas emissions and sustainability reporting and leads PwC's global technical working group focused on GHG.Colin Powell is PwC Canada's Technical Net Zero Leader, specializes in GHG quantification, life cycle assessment, target setting, and decarbonization strategies. He has helped companies measure over 1 billion tonnes of GHG emissions and advised global clients on decarbonization. Colin sits on the GHG Protocol's Scope 3 Working Group, shaping global standards, and is a Professional Engineer with a PhD in wastewater treatment modeling.About our hostHeather Horn is the PwC National Office Sustainability & Thought Leader, responsible for developing our communications strategy and conveying firm positions on accounting, financial reporting, and sustainability matters. In addition, she is part of PwC's global sustainability leadership team, developing interpretive guidance and consulting with companies as they transition from voluntary to mandatory sustainability reporting.Transcripts available upon request for individuals who may need a disability-related accommodation. Please send requests to us_podcast@pwc.comDid you enjoy this episode? Text us your thoughts and be sure to include the episode name.

A hostage return and the signing of a cease-fire agreement signal a new chapter in the long-running dream of peace in the Middle East. Did it matter that the key negotiators, on the US side, were financiers and real-estate developers rather than scions of America's diplomatic corps? Russell Berman, a Hoover Institution senior fellow and codirector of Hoover's Working Group on the Middle East and the Islamic World, joins GoodFellows regulars Niall Ferguson and John Cochrane to discuss the sturdiness of the Trump White House's 20-point peace plan, the futures of Hamas and the Abraham Accords, the likelihood of Israeli Prime Minister Benjamin Netanyahu's reliving Winston Churchill's fate (a successful wartime leader rejected by a war-weary electorate), plus whether the “real estate-ism” approach to diplomacy is applicable to President Trump's upcoming meetings with his Russian and Chinese counterparts. After that, Niall and John reflect on the likelihood of a market crash (it is October, after all), the chances of a full-fledged tariff war with China, the merits of a US-Argentina currency swap, plus an ominous warning from the International Monetary Fund regarding global debt. Finally, the fellows salute the legendary economist Thomas Sowell, the subject of a Hoover Institution tribute later this month.   Subscribe to GoodFellows for clarity on today's biggest social, economic, and geostrategic shifts — only on GoodFellows.

Thank you to the folks at Sustain (https://sustainoss.org/) for providing the hosting account for CHAOSSCast! CHAOSScast – Episode 121 In this episode of the CHAOSScast, host Alice Sowerby sits down with Andrew Nesbitt and Damián Vicino to discuss the formation and objectives of the new Package Metadata Working Group within the CHAOSS community. They discuss the complex issues surrounding package manager metadata, its interoperability challenges, and how the working group aims to address these through mapping and standardization efforts. They also touch upon the importance of these efforts for various stakeholders, including developers, researchers, and tool builders. The conversation highlights both the immediate and long-term goals of the group and provides information on how interested individuals can get involved. Hit download now to hear more! [00:00:26] Introductions from Alice, Andrew, and Damián. [00:02:36] Damián explains how the Package Metadata Working Group started. [00:04:33] Andrew shares his experience building mappings across multiple package registries and how differing field names, schema structures, and metadata definitions complicate consistency. [00:10:21] Alice asks about the group's short and long term objectives and Andrew outlines some immediate goals. [00:14:52] Damián elaborates on challenges in semantics and timelines. He emphasizes that even identically names fields may carry different meanings and shares an example. [00:18:46] Alice summarizes Damián's point saying the group's role is to provide guidance and analysis rather than enforce standards, helping maintainers make informed metadata decisions. [00:19:25] Andrew adds that most package managers evolve independently without referencing past ones. The working group's documentation aims to prevent repeated mistakes and guide new ecosystems toward interoperable designs. [00:23:06] Damián notes that modern software projects often depend on multiple ecosystems, making license tracking and dependency management exponentially harder without interoperability. [00:25:02] Andrew explains how researchers waste time rebuilding metadata mapping from scratch across ecosystems and having unified references would accelerate research and tool development. [00:27:58] Damián discusses how better metadata could support academic credit and funding by enabling easier citation and recognition of open source contributions tied to research projects. [00:29:39] How can you get involved? Damián invites package manager developers and metadata tool builders to join, and Andrew encourages anyone working with SBOMs or package metadata tools to contribute war stories, mapping, or research use cases. [00:33:01] Andrew mentions all the places you can join in on the meetings and to share where you are interested in working on. Value Adds (Picks) of the week: [00:35:25] Alice's pick is apples. [00:36:17] Damián's pick is hockey. [00:37:04] Andrew's pick is puppy training. Panelist: Alice Sowerby Guests: Andrew Nesbitt Damián Vicino Links: CHAOSS (https://chaoss.community/) CHAOSS Project X (https://twitter.com/chaossproj?lang=en) CHAOSScast Podcast (https://podcast.chaoss.community/) CHAOSS YouTube (https://www.youtube.com/@CHAOSStube/videos) podcast@chaoss.community (mailto:podcast@chaoss.community) Alice Sowerby LinkedIn (https://www.linkedin.com/in/alice-sowerby-ba692a13/?originalSubdomain=uk) Andrew Nesbitt Website (https://nesbitt.io/) Andrew Nesbitt GitHub (https://github.com/andrew) Andrew Nesbitt Mastodon (https://mastodon.social/@andrewnez) Damián Vicino LinkedIn (https://www.linkedin.com/in/dvicino/) Damián Vicino GitHub (https://github.com/sdavtaker) CHAOSSWG: Package Metadata (https://github.com/chaoss/wg-package-metadata) CHAOSS Calendar (https://chaoss.community/chaoss-calendar/) CHAOSS Slack (https://chaoss-workspace.slack.com/join/shared_invite/zt-r65szij9-QajX59hkZUct82b0uACA6g#/shared-invite/email) Special Guests: Andrew Nesbitt and Damián Vicino.

On this episode of JHLT: The Podcast, the Digital Media Editors invite co-lead author Nir Uriel, MD, Director of Advanced Heart Failure and Cardiac Transplantation at New York Presbyterian Hospital and Professor of Medicine at Columbia University. Dr. Uriel joins to discuss the work of the Cardiogenic Shock Working Group (CSWG) and their recent paper, “Outcomes of patients supported on Impella 5.5 for more than 14 days: A Cardiogenic Shock Working Group registry analysis.” The discussion explores: Why patients on longer duration of MCS had better survival but maintained similar rates of serious adverse events (SAEs) Why the study might show fewer SAEs than the literature historically shows How temporary MCS devices are selected in clinical settings in patients with cardiogenic shock The ongoing and upcoming activities of CSWG For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

Voices is a new mini-series from Humanitarian AI Today. In daily five-minute flashpods we pass the mic to innovators, researchers and practitioners on the humanitarian front lines, delivering real-time news on how they are building, testing and collaborating on uses of artificial intelligence. In this flashpod, Petya Kangalova, Technology Partnerships and Engagement Lead with Humanitarian Open Street Map joins Brent Phillips, Humanitarian AI Today podcast Producer, to discuss Humanitarian Open Street Map's Technology and Innovation Working Group, its monthly working group open discussion sessions and how people can tune-in. Substack Notes: https://humanitarianaitoday.substack.com/p/petya-kangalova-introduces-humanitarian

“We Speak CVE” podcast host Shannon Sabens chats with CVE Consumer Working Group (CWG) co-chairs, Jay Jacobs and Bob Lord, and CVE™ Project Lead Alec Summers, about how the CWG was created to address the needs and perspectives of those who use CVE data — ranging from enterprise security teams to tool developers and managed security service providers — recognizing that their requirements and pain points often differ from those of upstream data providers.Topics include the CWG's goals to systematically capture and organize consumer feedback, identify common and unique challenges across different user types, and inform improvements in the CVE Program; the diversity and international participation among sign-ups, including organizations outside the usual sphere, such as medical companies; and the concept of “patch smarter, not harder,” stressing the importance of prioritization and high-quality data to help defenders manage the overwhelming volume of vulnerabilities. In addition, listeners are encouraged to join the CWG for meetings scheduled to accommodate global involvement and help participate in shaping the future of CVE.

Clement Manyathela speaks to Imraan Patel and Anneline Morgan about the G20 3rd research and innovation working group and ministerial meeting happening today. They touch on South Africa's approach to technology, research and innovation as we approach the G20 summit. The Clement Manyathela Show is broadcast on 702, a Johannesburg based talk radio station, weekdays from 09:00 to 12:00 (SA Time). Clement Manyathela starts his show each weekday on 702 at 9 am taking your calls and voice notes on his Open Line. In the second hour of his show, he unpacks, explains, and makes sense of the news of the day. Clement has several features in his third hour from 11 am that provide you with information to help and guide you through your daily life. As your morning friend, he tackles the serious as well as the light-hearted, on your behalf. Thank you for listening to a podcast from The Clement Manyathela Show. Listen live on Primedia+ weekdays from 09:00 and 12:00 (SA Time) to The Clement Manyathela Show broadcast on 702 https://buff.ly/gk3y0Kj For more from the show go to https://buff.ly/XijPLtJ or find all the catch-up podcasts here https://buff.ly/p0gWuPE Subscribe to the 702 Daily and Weekly Newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook https://www.facebook.com/TalkRadio702 702 on TikTok https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 See omnystudio.com/listener for privacy information.

Clement Manyathela speaks to Prof Phillip Diamond, Director General at the Square Kilometer Array (SKA) Observatory on the importance of showing the delegates the work and research done at the Square Kilometer Array Observatory. They reflect on the importance of furthering knowledge of the universe. The Clement Manyathela Show is broadcast on 702, a Johannesburg based talk radio station, weekdays from 09:00 to 12:00 (SA Time). Clement Manyathela starts his show each weekday on 702 at 9 am taking your calls and voice notes on his Open Line. In the second hour of his show, he unpacks, explains, and makes sense of the news of the day. Clement has several features in his third hour from 11 am that provide you with information to help and guide you through your daily life. As your morning friend, he tackles the serious as well as the light-hearted, on your behalf. Thank you for listening to a podcast from The Clement Manyathela Show. Listen live on Primedia+ weekdays from 09:00 and 12:00 (SA Time) to The Clement Manyathela Show broadcast on 702 https://buff.ly/gk3y0Kj For more from the show go to https://buff.ly/XijPLtJ or find all the catch-up podcasts here https://buff.ly/p0gWuPE Subscribe to the 702 Daily and Weekly Newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook https://www.facebook.com/TalkRadio702 702 on TikTok https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 See omnystudio.com/listener for privacy information.

Gov. Tim Walz says when the regular legislative session starts next February, he'd like to revisit legislation that did NOT get passed in 2023. Walz says a tax credit for child care could help ease the high cost for families.And leaders of a Minnesota Senate working group on gun violence prevention are gearing up for meetings next week.Those stories and more in today's evening update from MPR News. Hosted by Emily Reese. Music by Gary Meister.

In this episode, we are joined by Marietje Schaake, former Member of the European Parliament, to unpack the EU AI Act Code of Practice. Schaake served as Chair of the Working Group on Internal Risk Management and Governance of General-Purpose AI Providers for the Code of Practice, with a focus on AI model safety and security. We discuss the development and drafting of the EU AI Act and Code of Practice (16:47), break down how the Code helps AI companies demonstrate compliance with the Act (28:25), and explore the kinds of systemic risks the AI Act seeks to address (32:00).

In this episode, I discuss a possible circuit of working collar-and-elbow wrestlers in the 1860s and 1870s.

Did you know that the IRS has working group meetings for the Information Returns Intake System (IRIS)?  To find out three things I learned when I attended, what the IRS says FIRE users should do now and how you can attend the next one..Keep listening. Check out my website www.debrarrichardson.com if you need help implementing authentication techniques, internal controls, and best practices to prevent fraudulent payments, regulatory fines or bad vendor data. Check out the Vendor Process Training Center for 116+ hours of weekly live and on-demand training for the Vendor team. Links mentioned in the podcast + other helpful resources:     YouTube Video:  Demo of the IRS e-News Subscriptions IRS: IRIS working group meetings and notes Customized Vendor Validations Session: https://debrarrichardson.com/vendor-validation-sessionVendor Process Training Center - https://training.debrarrichardson.comCustomized Fraud Training:  https://training.debrarrichardson.com/customized-fraud-training Free Live and On-Demand Webinars: https://training.debrarrichardson.com/webinarsVendor Master File Clean-Up:  https://www.debrarrichardson.com/cleanupYouTube Channel:  https://www.youtube.com/channel/UCqeoffeQu3pSXMV8fUIGNiw More Podcasts/Blogs/Webinars www.debrarrichardson.comMore ideas?  Email me at debra@debrarrichardson.com Music Credit:  www.purple-planet.com

Join our hosts as they sit down with Stephen Patane, Vice President of Crypto and Digital Assets Policy at Fidelity Investments, to unpack the evolving landscape of U.S. crypto regulation. We'll explore key provisions of recent legislation, how federal agencies are responding to these changes, and key takeaways for stakeholders across the DeFi landscape.   Episode Topics: [0:00] Intro [2:00] Ethereum Turns Ten [4:45] Welcome to Stephen Patane [6:34] A Deep-dive into Recent Legislation [24:08] Updates from the President's Working Group [29:58] Outro       Stay connected with us beyond the podcast by following FCAT on Instagram, LinkedIn, and X where we share additional insights and updates on all things emerging tech. Whether you're crypto-curious or have a crypto foundation, Fidelity may have your next career opportunity. EXPLORE NOW. Please remember: this podcast is solely for informational and educational purposes and is not investment, tax, legal or insurance advice. Digital assets are speculative and highly volatile and you should conduct thorough research before you invest. To learn more, visit: fcatalyst.com FMR LLC. © 2025 FMR LLC. All rights reserved. Chapters (00:00:00) - Intro(00:02:00) - Ethereum Turns Ten(00:04:45) - Welcome to Stephen Patane(00:06:34) - A Deep-dive into Recent Legislation(00:24:08) - Updates from the President's Working Group(00:29:58) - Outro

- Samourai Wallet Developers Plead Guilty To Unlicensed Money Transmission https://www.therage.co/samourai-wallet-developers-plead-guilty-to-unlicensed-money-transmission/- Tornado Cash Verdict Expected Today https://www.therage.co/the-storm-jurys-dilemma-was-crime-the-goal-all-along/- Spotify users told to prove their age under new rules https://www.the-independent.com/tech/spotify-age-checks-verification-b2798937.html- YouTube's new AI age verification is coming soon — here's what's going to change https://www.tomsguide.com/ai/youtubes-new-ai-age-verification-is-coming-soon-heres-whats-going-to-change- X Implements Age Checking Measures To Align With New Laws https://www.socialmediatoday.com/news/x-formerly-twitter-adds-new-age-verification-measures/754024/ + https://x.com/globalaffairs/status/1927697128219947132- Trump blasts Powell after Fed votes to keep interest rates steady https://thehill.com/homenews/administration/5429281-donald-trump-jerome-powell-interest-rates/- The President's Working Group on Digital Asset Markets Releases Recommendations to Strengthen American Leadership in Digital Financial Technology https://www.whitehouse.gov/crypto/ + nevent1qvzqqqqqqypzquq0mq9wdrsqnmf6jly595nxud0c5j3zd3cf4hzr0tck4wxstfunqqsg4vv7vhcmspkl2uetkme8pyx9thgyskmjg2q3una2hh0n9xdyr7sqyhcj0-Fold and Blackhawk Network Bring Bitcoin to Major U.S. Digital Retail Platforms https://investor.foldapp.com/news-releases/news-release-details/fold-and-blackhawk-network-bring-bitcoin-major-us-digital-retail- AnchorWatch has officially completed its SOC 2 Type 1 audit https://x.com/anchorwatch/status/1950579169877791173- El Salvador | New Insights Reveal Bitcoin DeceptionA new detail buried in an IMF progress report casts doubt on El Salvador's claim that it is “buying one Bitcoin a day.” According to the IMF, “increases in Bitcoin holdings in the Strategic Reserve Fund reflect the consolidation of Bitcoin across various government-owned wallets.” This suggests that President Nayib Bukele's progressively authoritarian government may be reshuffling existing Bitcoin holdings from undisclosed wallets rather than accumulating new Bitcoin. A letter signed by two of El Salvador's top finance officials also confirmed the state has not bought Bitcoin since February 2025. The revelation comes after El Salvador secured a $1.4 billion IMF loan, which required the government to scale back key parts of its Bitcoin policy, including ending tax payments in Bitcoin, phasing out the Chivo wallet, and making private sector acceptance voluntary. While Bukele continues to tout Bitcoin as part of El Salvador's identity, the disconnect between official actions and public messaging calls into question transparency and credibility. FinancialFreedomReport.org- Bitchat 1.2.0 iOS and bitchat android 0.8.1 https://github.com/permissionlesstech/bitchat-android/releases/tag/0.8.1- MSTR Earnings Today0:00 - Intro2:35 - Welcome back to Car Talk10:31 - Zora18:28 - Dashboard20:39 - Samourai34:28 - Age verification46:50 - Gaza story and psyops50:25 - Patriot Act extension and dead internet1:08:13 - Fold + Blackhawk1:11:11 - AnchorWatch SOC 2 Audit1:13:22 - Simplicity Liquid1:20:00 - peer-observer1:24:46 - HRF Story of the Week1:27:44 - Bitchat1:38:05 - Paper bitcoin newsShoutout to our sponsors:Coinkitehttps://coinkite.com/Bitkeyhttps://bitkey.world/Stakworkhttps://stakwork.ai/Follow Marty Bent:Twitterhttps://twitter.com/martybentNostrhttps://primal.net/martyNewsletterhttps://tftc.io/martys-bent/Podcasthttps://tftc.io/podcasts/Follow Odell:Nostrhttps://primal.net/odellNewsletterhttps://discreetlog.com/Podcasthttps://citadeldispatch.com/

Osteosarcoma Webinar Series: Amanda Marinoff, MD, a physician-scientist from UCSF will discuss clinical biomarkers for osteosarcoma stratification (cBOSS): Insights from a working group.Despite decades of research, osteosarcoma remains one of the few pediatric cancers without validated molecular biomarkers to guide treatment. The Clinical Biomarkers for Osteosarcoma Stratification (cBOSS) initiative is an international effort to change that. Modeled after a successful framework in Ewing sarcoma, cBOSS convened experts from North America and Europe to systematically evaluate emerging molecular features with the greatest potential for near-term clinical translation. Through a series of structured sessions, the group assessed the biological plausibility, clinical relevance, and implementation feasibility of candidate classifiers across five domains: genomic, transcriptomic, epigenetic, immune, and circulating analytes. This webinar will provide an overview of the cBOSS approach, key findings to date, including the maturity of circulating tumor DNA and MYC amplification as prognostic tools, and the path forward for incorporating molecular stratification into future clinical trials. The goal: to move beyond one-size-fits-all therapy and build a precision medicine framework for osteosarcoma.Dr. Amanda Marinoff is a pediatric oncologist and translational researcher at UCSF, where she focuses on developing molecular biomarkers to improve risk stratification and treatment for children and young adults with osteosarcoma. She co-leads the international cBOSS initiative (Clinical Biomarkers for Osteosarcoma Stratification), which brings together experts across North America and Europe to evaluate and prioritize emerging classifiers for clinical use. Her research aims to bridge the gap between genomic discovery and therapeutic application, advancing precision medicine approaches for patients with high-risk disease. Dr. Marinoff earned her medical degree from Harvard Medical School, completed her pediatrics residency at Boston Children's Hospital, and completed her pediatric hematology/oncology fellowship at UCSF Benioff Children's Hospital. She is an active member of the pediatric solid tumor and early-phase clinical trials groups at UCSF.

Crypto News: The President's Working Group on Digital Asset Markets released a report that provides a roadmap to USHER IN THE GOLDEN AGE OF CRYPTO. Coinbase partners with Chase bank to accelerate crypto adoption.Show Sponsor -

We have a special (and timely) conversation today with Grazyna Baranowska, Vice Chair of the UN Working Group on Enforced or Involuntary Disappearances. Anjali Dayal and Dr. Baranowska discuss the International Convention for the Protection of All Persons from Enforced Disappearance and the kinds of investigations the Working Group has undertaken — in particular, the Working Group's critical efforts to uncover details about the detention of Venezuelan migrants by the United States in a maximum-security prison in El Salvador. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.globaldispatches.org/subscribe

Crypto News: The crypto market cools down as Altcoins hit the overbought zone. The President's Working Group on Digital Assets has completed the 180-day report. It will be released publicly on July 30th. Goldman Sachs, BNY to offer tokenized money market funds for clients.Show Sponsor -

In this episode of SurgOnc Today, the SSO Colorectal Disease Site Working Group will recap content from the 2025 American Society of Colorectal Surgeons (ASCARS) and Society of Surgery of the Alimentary Tract (SSAT) programs. Broad highlights of both benign and malignant disease conditions are covered. This episode is hosted by Dr. Jennifer Miller-Ocuin, Dr. Jitesh Patel, Dr. Abhineet Uppal, and Dr. Prakash Pandalai. They cover hot topics, areas of controversy, and new research shared across various specialties including colorectal surgery, surgical oncology, gastroenterology, basic, and translational sciences. We hope you will enjoy this recap.

Drug buying agency Pharmac is bringing patients and consumers to the table. Chair of the new group Dr Malcolm Mulholland spoke to Corin Dann.

Send us a textHealthcare providers should be concerned. In this episode, Captain Integrity Bob Wade explores the new DOJ and HHS False Claims Act Working Group targeting healthcare fraud with Knicole Emanuel, Partner at Nelson Mullins. Hear why you should review your compliance program, reassess your risk exposure, consider voluntary disclosure, the areas the working group is targeting, and why this is a paradigm shift for the healthcare industry. Learn more at CaptainIntegrity.com 

Nicci Wright–co-founder and co-chairperson of the African Pangolin Working Group (APWG), dedicated to the protection and the conservation of the pangolin, the world's most trafficked animal—recalls her first encounter with a pangolin more than two decades ago. Echoing a response commonly experienced after individuals are introduced to these striking-looking animals, Wright felt compelled to help […] The post Nicci Wright, co-founder of the African Pangolin Working Group first appeared on Talking Animals.

Jon Hartley and Randal Quarles discuss Randy's career as a lawyer and in policy (including his time as Federal Reserve Vice Chair for Regulation) and topics such as the global financial crisis, Glass-Steagall, banking regulation, lender of last resort, Basel III, the Dodd-Frank Act, capital requirements, the potential relaxation of Treasuries in the Supplementary Leverage Ratio (SLR), deposit insurance after the Silicon Valley Bank regional banking crisis, and stablecoin regulation. Recorded on May 29, 2025. ABOUT THE SPEAKERS: Randal Quarles is the Chairman and co-founder of The Cynosure Group.  Before founding Cynosure, Mr. Quarles was a long-time partner of the Carlyle Group, where he began the firm's program of investments in the financial services industry during the 2008 financial crisis. From October 2017 through October 2021, Mr. Quarles was Vice Chairman of the Federal Reserve System, serving as the system's first Vice Chairman for Supervision, charged specifically with ensuring stability of the financial sector.  He also served as the Chairman of the Financial Stability Board (“FSB”) from December 2018 until December 2021; a global body established after the Great Financial Crisis to coordinate international efforts to enhance financial stability. In both positions, he played a key role in crafting the US and international response to the economic and financial dislocations of COVID-19, successfully preventing widespread global disruption of the financial system.  As FSB Chairman, he was a regular delegate to the finance ministers' meetings of the G-7 and G20 Groups of nations and to the Summit meetings of the G20.  As Fed Vice Chair, he was a permanent member of the Federal Open Market Committee, the body that sets monetary policy for the United States. Earlier in his career, Mr. Quarles was Under Secretary of the U.S. Treasury, where he led the Department's activities in financial sector and capital markets policy, including coordination of the President's Working Group on Financial Markets. Before serving as Under Secretary, Mr. Quarles was Assistant Secretary of the Treasury for International Affairs, where he had a key role in responding to several international crises.  Mr. Quarles was also the U.S. Executive Director of the International Monetary Fund, a member of the Air Transportation Stabilization Board, and a board representative for the Pension Benefit Guaranty Corporation. In earlier public service, he was an integral member of the Treasury team in the George H. W. Bush Administration that developed the governmental response to the savings and loan crisis. Jon Hartley is currently a Policy Fellow at the Hoover Institution, an economics PhD Candidate at Stanford University, a Research Fellow at the UT-Austin Civitas Institute, a Senior Fellow at the Foundation for Research on Equal Opportunity (FREOPP), a Senior Fellow at the Macdonald-Laurier Institute, and an Affiliated Scholar at the Mercatus Center. Jon is also the host of the Capitalism and Freedom in the 21st Century Podcast, an official podcast of the Hoover Institution, a member of the Canadian Group of Economists, and the chair of the Economic Club of Miami. Jon has previously worked at Goldman Sachs Asset Management as a Fixed Income Portfolio Construction and Risk Management Associate and as a Quantitative Investment Strategies Client Portfolio Management Senior Analyst and in various policy/governmental roles at the World Bank, IMF, Committee on Capital Markets Regulation, U.S. Congress Joint Economic Committee, the Federal Reserve Bank of New York, the Federal Reserve Bank of Chicago, and the Bank of Canada.  Jon has also been a regular economics contributor for National Review Online, Forbes, and The Huffington Post and has contributed to The Wall Street Journal, The New York Times, USA Today, Globe and Mail, National Post, and Toronto Star, among other outlets. Jon has also appeared on CNBC, Fox Business, Fox News, Bloomberg, and NBC and was named to the 2017 Forbes 30 Under 30 Law & Policy list, the 2017 Wharton 40 Under 40 list, and was previously a World Economic Forum Global Shaper.  ABOUT THE SERIES: Each episode of Capitalism and Freedom in the 21st Century, a video podcast series and the official podcast of the Hoover Economic Policy Working Group, focuses on getting into the weeds of economics, finance, and public policy on important current topics through one-on-one interviews. Host Jon Hartley asks guests about their main ideas and contributions to academic research and policy. The podcast is titled after Milton Friedman‘s famous 1962 bestselling book Capitalism and Freedom, which after 60 years, remains prescient from its focus on various topics which are now at the forefront of economic debates, such as monetary policy and inflation, fiscal policy, occupational licensing, education vouchers, income share agreements, the distribution of income, and negative income taxes, among many other topics.

Drs. Pemmaraju and Bose discuss the revised International Working Group criteria for anemia response in patients with myelofibrosis, outlining new definitions for transfusion status, gender-specific hemoglobin thresholds, and benchmarks for major and minor responses.

Today we cover the headlines from the weekend including the Governors call for a post session creation of a 'working group' to deliver a fiscal plan. (didn't we do this already?) Then in hour two we'll visit with David Boyle who'll come in and talk to us about the truth in funding for the ASD as well as other school districts.

In an Information Age during which decentralized news and information have contributed to a greater lack of trust in government and traditional media outlets, is it possible to restore confidence in both institutions? Nick Mastronardi, a Hoover Institution veteran fellow and software innovator in the field of public-sector communications, discusses advances in data collection and artificial intelligence and a positive impact on government behavior with Hoover Volker Senior Fellow (adjunct) “Checker” Finn, one of the nation's preeminent authorities on education policy and innovation. Recorded on January 14, 2025.  ABOUT THE SERIES Educators across the land are preparing for Civic Learning Week in mid-March—with the capstone National Forum at the Hoover Institution on March 13—as the nation also gets ready for next year's 250th anniversary of the Declaration of Independence. In anticipation of both—and recognizing the urgent need to rekindle civic literacy via our schools and colleges—Renewing Civics Education – Preparing for American Citizenship, a five-part podcast series, takes on the challenges of citizenship education: why it matters, what it needs to do differently, what shortcomings it must overcome. The series features distinguished members of Hoover's Working Group on Good American Citizenship, led by Volker Senior Fellow Chester Finn.

On Sunday, President Donald Trump namedfive digital assets — Bitcoin, Ether, XRP, Solana, and Cardano — that will make up a “Crypto Strategic Reserve” for the United States. The announcement follows Trump's January 23 executive orderestablishing the Working Group on Digital Asset Markets, which is tasked with evaluating the creation of a strategic stockpile of national digital assets. Ad-free podcasts are here!Many listeners have been asking for an ad-free version of this podcast that they could subscribe to — and we finally launched it. You can go to ReadTangle.com to sign up!You can read today's podcast⁠ ⁠⁠here⁠⁠⁠, our “Under the Radar” story ⁠here and today's “Have a nice day” story ⁠here⁠.Take the survey: What do you think of establishing a U.S. cryptocurrency reserve? Let us know!You can subscribe to Tangle by clicking here or drop something in our tip jar by clicking here. Our Executive Editor and Founder is Isaac Saul. Our Executive Producer is Jon Lall.This podcast was written by Isaac Saul and edited and engineered by Dewey Thomas. Music for the podcast was produced by Diet 75.Our newsletter is edited by Managing Editor Ari Weitzman, Senior Editor Will Kaback, Hunter Casperson, Kendall White, Bailey Saul, and Audrey Moorehead. Our logo was created by Magdalena Bokowa, Head of Partnerships and Socials. Hosted on Acast. See acast.com/privacy for more information.

Does a Stanford University initiative reinstating a century-old tradition of American civics learning offer a roadmap for the future of higher education? In this installment, Josiah Ober, a Hoover Institution senior fellow and a Stanford professor taking part in the Stanford Civics Initiative, discusses the path forward in citizenship education with Volker Senior Fellow (adjunct) “Checker” Finn, one of the nation's preeminent authorities on education policy and innovation. Recorded January 9, 2025.  ABOUT THE SERIES Educators across the land are preparing for Civic Learning Week in mid-March—with the capstone National Forum at the Hoover Institution on March 13—as the nation also gets ready for next year's 250th anniversary of the Declaration of Independence. In anticipation of both—and recognizing the urgent need to rekindle civic literacy via our schools and colleges—Renewing Civics Education – Preparing for American Citizenship, a five-part podcast series, takes on the challenges of citizenship education: why it matters, what it needs to do differently, what shortcomings it must overcome. The series features distinguished members of Hoover's Working Group on Good American Citizenship, led by Volker Senior Fellow Chester Finn.

Discover what the "Working Group on Crypto" is. Are you investing well for financial freedom...or not? Financial freedom is a combination of money, compounding and time (my McT Formula). How well you invest, makes a huge difference to your financial future and lifestyle. If you only knew where to invest for the long-term, what a difference it would make, because the difference between investing $100k and earning 5 percent or 10 percent on your money over 30 years, is the difference between it growing to $432,194 or $1,744,940, an increase of over $1.3 million dollars. Your compounding rate, and how well you invest, matters!  INTERESTED IN THE BE WEALTHY & SMART VIP EXPERIENCE? - Invest in stock ETFs, private equity and digital assets for potential high compounding rates - Asset allocation model with ticker symbols and % to invest -Monthly LIVE investment updates with Linda, with Q & A -Private VIP Facebook group with daily interaction -Weekly investment commentary from Linda -Optional 1-on-1 tech team support for digital assets -Join, pay once, have lifetime access! NO recurring fees. -US and foreign investors, no minimum $ amount to invest For the holidays, enjoy a 50% savings on my private investing group, the Be Wealthy & Smart VIP Experience. Pay once and enjoy lifetime access without any additional cost. Enter "SAVE50" to save 50% here: http://tinyurl.com/InvestingVIP Or have a complimentary conversation to answer your questions. Request a free appointment to talk with Linda here: https://tinyurl.com/TalkWithLinda (yes, you talk to Linda!). WANT TO INVEST IN STOCKS PRE-IPO? #Ad Accredited Investors invest in top-notch private companies (pre-IPO) with Linqto. First investment minimum is only $1k. Sign up to receive a $500 credit toward your investment, here: https://tinyurl.com/LindaLinqto WANT HELP AVOIDING IRS AUDITS? #Ad Stop worrying about IRS audits and get advance warning at Crypto Tax Audit, here. PLEASE REVIEW THE PODCAST ON ITUNES If you enjoyed this episode, please subscribe and leave a review. I love hearing from you! I so appreciate it! SUBSCRIBE TO BE WEALTHY & SMART Click Here to Subscribe Via iTunes Click Here to Subscribe Via Stitcher on an Android Device Click Here to Subscribe Via RSS Feed   PLEASE LEAVE A BOOK REVIEW FOR THE CRYPTO INVESTING BOOK Get my book, "3 Steps to Quantum Wealth: The Wealth Heiress' Guide to Financial Freedom by Investing in Cryptocurrencies". After you purchase the book, go here for your Crypto Book bonus: https://lindapjones.com/bookbonus PLEASE LEAVE A BOOK REVIEW FOR WEALTH BOOK Leave a book review on Amazon here. Get my book, “You're Already a Wealth Heiress, Now Think and Act Like One: 6 Practical Steps to Make It a Reality Now!” Men love it too! After all, you are Wealth Heirs. :) Available for purchase on Amazon. International buyers (if you live outside of the US) get my book here. WANT MORE FROM LINDA? Check out her programs. Join her on Instagram. WEALTH LIBRARY OF PODCASTS Listen to the full wealth library of podcasts from the beginning. Use the search bar in the upper right corner of the page to search topics. SPECIAL DEALS #Ad Protect yourself online with a Virtual Private Network (VPN). Get 3 MONTHS FREE when you sign up for a NORD VPN plan here.  #Ad To safely and securely store crypto, I recommend using a Tangem wallet. Get a 10% discount when you purchase here. #Ad If you are looking to simplify your crypto tax reporting, use Koinly. It is highly recommended and so easy for tax reporting. You can save $20, click here. Be Wealthy & Smart,™ is a personal finance show with self-made millionaire Linda P. Jones, America's Wealth Mentor.™ Learn simple steps that make a big difference to your financial freedom.  (Some links are affiliate links. There is no additional cost to you.)

Bitcoin is up slightly at $105,499 Eth is up half a percent at $3,415 XRP, down half a percent at $3.19 Trump orders creation of Working Group on Digital Asset Markets Trump tells Davos the US will become the world capital of AI and crypto NK hackers suspected in hack of Phemex THORChain pauses THOREFi services SignalPlus raises series B Learn more about your ad choices. Visit megaphone.fm/adchoices